Patients with colon cancer who followed the American Cancer Society’s Nutrition and Physical Activity Guidelines for Cancer Survivors have improved 5-year survival rates.

Conferences

The physical location of a primary tumor may be an indicator of survivor in patients with metastatic colorectal cancer (mCRC), according to results from a large retrospective study presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL (June 3-7, 2016).

Read More

News

The incidence of young onset colorectal cancer has increased significantly since the 1990s among individuals aged 20 to 49 years, according to a report from the Colorectal Cancer Alliance.
Systemic inflammation and sarcopenia have high potential as biomarkers for clinical use in prognostication and in guiding intervention.

A recent study examined the association between colorectal cancer messenger RNA (mRNA) expression of HER3 with response to anti-EGFR agents, published in JAMA Oncology (online October 26, 2017; doi:10.1001/jamaoncol.2017.3168).

Read More

A pooled analysis investigated the prognostic role of DNA mismatch repair (MMR) status in patients with stage III colon cancer treated with a standard adjuvant chemotherapy regimen, published in JAMA Oncology (online October 5, 2017; doi:10.1001/jamaoncol.2017.2899).

Read More

Research in Review

Over-the-counter heartburn and gastrointestinal drugs, such as proton pump inhibitors (PPIs), may decrease the effectiveness of chemotherapy in patients with gastroesophageal cancer (GEC), according to a new study published in JAMA Oncology.

-----

Related Content

Read More

The recently published US Preventative Services Task Force (USPSTF) updated recommendation statement on colorectal cancer screening referenced multiple available options for colorectal screening, including Epigenomics’ Epi proColon.

Read More

Patients with stage II or stage III rectal cancer may have better outcomes when treated with surgery and chemoradiotherapy than those who receive chemoradiotherapy alone, according to an article published in JAMA Oncology.

Read More

There is no benefit from the addition of bevacizumab to capecitabine in the adjuvant setting for colorectal cancer, according to results from a clinical trial.

Read More

Subscribe to Colorectal Cancer